Compared with the newly diagnosed, untreated lung cancer group, there were significant changes in carnitine, amino acids, fatty acids, and lipids in the EGFR-TKI- and PD-1/PD-L1 inhibitor-treated groups. This evidence concerns the gene CD274 and lung cancer.